Kane Biotech Inc (TSE:KNE)
:KNE
Top Page
Kane Biotech
(KNE)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.04
▲(26.67% Upside)
Action:ReiteratedDate:12/18/25
Kane Biotech's overall stock score is primarily impacted by its poor financial performance, which poses significant risks. Technical analysis supports a bearish outlook, and valuation metrics are unattractive due to ongoing losses. The lack of earnings call and corporate events data limits additional insights, but the existing data indicates a challenging investment environment.
Positive Factors
Patented Antimicrobial Technology
Kane Biotech’s focus on patented antimicrobial and anti-biofilm technologies represents a durable competitive advantage. Patents and specialized science underpin barriers to entry, support pricing power in niche clinical, veterinary and industrial markets, and enable long-term licensing and product differentiation.
Negative Factors
Severe Revenue Decline
A near 69% revenue drop is a structural red flag: it erodes economies of scale, weakens market positioning, and constrains reinvestment in R&D and commercialization. Sustained top-line contraction undermines the company’s ability to translate its IP and partnerships into durable, profitable growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Patented Antimicrobial Technology
Kane Biotech’s focus on patented antimicrobial and anti-biofilm technologies represents a durable competitive advantage. Patents and specialized science underpin barriers to entry, support pricing power in niche clinical, veterinary and industrial markets, and enable long-term licensing and product differentiation.
Read all positive factors
Kane Biotech (KNE) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$5.46M
Dividend YieldN/A
Average Volume (3M)112.95K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
Employees32
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding181,846,560
10 Day Avg. Volume120,057
30 Day Avg. Volume112,955
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-9.04
Price to Sales (P/S)7.08
P/FCF Ratio-3.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kane Biotech Business Overview & Revenue Model
Company Description
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care produ...
How the Company Makes Money
Kane Biotech generates revenue through multiple streams, including the sale of its proprietary antimicrobial products to healthcare providers, veterinary clinics, and industrial clients. The company also engages in licensing agreements, allowing o...
Kane Biotech Earnings Call Summary
Earnings Call Date:Nov 28, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:May 21, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth driven by new product sales and service revenue streams. Strategic partnerships, regulatory approvals, and expansion into new markets were noted as positive developments. However, increased operating expenses and a decrease in cash reserves were challenges mentioned. Overall, the positive developments notably outweigh the drawbacks.Positive Updates
Significant Increase in Product Sales
Product sales for Q3 2024 were $598,000 compared to $4,000 in Q3 2023, primarily due to the first commercial sales of revyve Antimicrobial Wound Gel to the U.S. distributor ProgenaCare.
Negative Updates
Increased Operating Expenses
Total operating expenses for Q3 2024 were $1,170,000, an increase of 18% compared to $995,000 for Q3 2023, due to higher employee compensation, consulting, travel, and investor relation expenses.
Read all updates
Q3-2024 Updates
Positive
Negative
Significant Increase in Product Sales
Product sales for Q3 2024 were $598,000 compared to $4,000 in Q3 2023, primarily due to the first commercial sales of revyve Antimicrobial Wound Gel to the U.S. distributor ProgenaCare.
Read all positive updates
Company Guidance
During Kane Biotech's Q3 2024 earnings call, the guidance highlighted several key achievements and future expectations. The company recorded its first commercial sales of revyve Antimicrobial Wound Gel, contributing to product sales of $598,000 for the quarter, compared to just $4,000 in Q3 2023. Total revenue reached $1,283,000, significantly up from $27,000 in the previous year, with a gross profit of $559,000. Operating expenses increased by 18% to $1,170,000. Despite these expenses, the net loss from continuing operations decreased by 45% to $679,000. Kane Biotech is anticipating further growth, with plans for additional distribution agreements, regulatory approvals, and the launch of new products, including DispersinB Wound Gel trials and potential enhancements to their Lumixa product. Additionally, a $3 million private placement was announced to support these initiatives.Kane Biotech Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
15
Very Negative
Cash Flow
25
Negative
| Breakdown | TTM | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 574.87K | 2.08M | 148.98K | 156.73K | 1.61M | 1.34M |
| Gross Profit | -131.63K | 872.10K | 109.47K | 1.41M | 568.44K | 526.86K |
| EBITDA | -2.77M | -3.71M | -3.23M | -2.95M | -4.25M | -3.65M |
| Net Income | -1.95M | -3.02M | -5.03M | -3.89M | -4.60M | -3.72M |
Balance Sheet | ||||||
| Total Assets | 2.74M | 2.49M | 5.68M | 5.62M | 6.13M | 5.04M |
| Cash, Cash Equivalents and Short-Term Investments | 939.06K | 358.81K | 749.25K | 1.10M | 1.15M | 1.01M |
| Total Debt | 2.30M | 2.29M | 9.26M | 6.86M | 4.71M | 2.25M |
| Total Liabilities | 3.53M | 4.12M | 14.09M | 9.76M | 7.70M | 3.96M |
| Stockholders Equity | -793.37K | -1.63M | -10.56M | -6.52M | -3.89M | -1.49M |
Cash Flow | ||||||
| Free Cash Flow | -3.09M | -4.14M | -3.23M | -3.13M | -2.64M | -4.07M |
| Operating Cash Flow | -2.99M | -4.11M | -3.22M | -3.04M | -2.29M | -3.94M |
| Investing Cash Flow | 348.00 | 10.27M | -116.14K | -107.55K | -373.55K | -166.11K |
| Financing Cash Flow | 3.39M | -7.69M | 2.98M | 3.10M | 2.81M | 4.28M |
Kane Biotech Technical Analysis
Negative
0.03
Price Trends
0.04
Negative
0.04
Negative
0.04
Negative
Market Momentum
>-0.01
Positive
35.77
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KNE, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.04, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.77 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:KNE.
Kane Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$6.00M | -0.15 | 123.88% | ― | ― | 90.81% | |
45 Neutral | C$4.01M | -4.13 | -41.36% | ― | -50.89% | -32.33% | |
42 Neutral | C$4.46M | -4.91 | -111.11% | ― | ― | -1939.32% | |
41 Neutral | C$5.46M | -3.10 | ― | ― | ― | ― | |
| ― | C$1.89M | -1.60 | ― | ― | ― | 25.09% |
* Healthcare Sector Average
TSE:KNE
Kane Biotech
0.03
-0.07
-70.00%
TSE:APS
Aptose Biosciences
2.35
-1.50
-38.96%
TSE:XRTX
XORTX Therapeutics Inc
3.20
-3.40
-51.52%
TSE:QPT
Quest Pharmatech
0.03
-0.03
-50.00%
TSE:BIOV
BioVaxys Technology
0.07
-0.39
-85.56%
TSE:MOOD
Doseology Sciences
0.50
0.03
5.26%
Kane Biotech Corporate Events
Private Placements and Financing
Kane Biotech Raises $700,000 in Insider-Led Private Placement
Neutral
Dec 18, 2025
Kane Biotech Inc. has closed a non-brokered private placement with an insider, issuing 14 million common shares at $0.05 per share for gross proceeds of $700,000, with the funds earmarked for working capital and general corporate purposes. The ins...
Business Operations and StrategyProduct-Related Announcements
Kane Biotech Showcases Advancements in Wound Care at Industry Meeting
Positive
Dec 17, 2025
Kane Biotech presented new clinical data at the Innovations in Wound Healing Annual Meeting, showcasing advancements in wound care and the efficacy of its products in treating diverse and complex conditions like chronic wounds and Hidradenitis Sup...
Business Operations and StrategyProduct-Related Announcements
Kane Biotech’s revyve Wound Gel Spray Gains Health Canada Approval
Positive
Dec 10, 2025
Kane Biotech has announced that its revyve Antimicrobial Wound Gel Spray has received approval from Health Canada, marking a significant regulatory milestone for the company. This approval allows Canadian clinicians and patients access to a new op...
Business Operations and StrategyFinancial Disclosures
Kane Biotech Reports Q3 2025 Results Amid Strategic Progress in Wound Care Market
Negative
Nov 28, 2025
Kane Biotech announced its third quarter 2025 financial results, revealing a significant decline in revenue and gross profit compared to the previous year, largely due to the termination of key agreements. Despite the financial setbacks, the compa...
Business Operations and StrategyPrivate Placements and Financing
Kane Biotech Launches $800,000 Private Placement Offering
Neutral
Nov 27, 2025
Kane Biotech Inc. has announced a non-brokered private placement offering of up to 16 million common shares at $0.05 per share, aiming to raise up to $800,000. The proceeds will be used for working capital and general corporate purposes, with the ...
Business Operations and StrategyProduct-Related Announcements
Kane Biotech’s revyve Gel Shows Promising Results in Wound Care
Positive
Nov 4, 2025
Kane Biotech recently presented promising clinical and pre-clinical data for its revyve Antimicrobial Wound Gel and Gel Spray at major U.S. medical conferences. The data showed significant improvements in diabetic foot ulcer healing and burn wound...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.